Promontory Therapeutics Inc., a clinical stage pharmaceutical company specializing in innovative treatments for cancer, has recently expanded its Phase 2 trial of PT-112 to include patients in France. This exciting development marks the company's first foray into the French market and brings hope to individuals with metastatic castrate-resistant prostate cancer (mCRPC).
The trial, which is currently ongoing, aims to evaluate the efficacy and safety of PT-112 in late-stage mCRPC patients. Four patients have already received treatment at prestigious medical institutions such as Gustave Roussy and the Military Hospital (HIA) Bégin in Paris. The study, registered under the ClinicalTrials.gov Identifier NCT02266745, seeks to determine the optimal dosage regimen for PT-112 through an open-label, multi-center proof of concept approach.
By expanding their trial to France, Promontory Therapeutics hopes to gather valuable data on the benefit-risk ratio of PT-112. This information will be crucial in advancing the drug's development and ultimately gaining approval from regulatory authorities like the FDA. In fact, this trial aligns with the